Rinsulin R, 100 me/ml 3 ml 5 pcs

Pharmacotherapeutic group: Hypoglycemic drug, short-acting insulin.

ATC code: A10AB01
Pharmacological properties

Pharmacodynamics

Rinsulin R is a human insulin produced using recombinant DNA technology. It is a short-acting insulin. It interacts with specific receptor of outer cytoplasmic cell membrane and forms insulin-receptor complex, which stimulates intracellular processes, including synthesis of several key enzymes (hexokinase, pyruvate kinase, glycogen synthase and others). Decrease of glucose content in blood is caused by an increase of its intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis, glycogenogenesis, decrease of glucose production rate by liver, etc.

The duration of action of insulin drugs is mainly due to the speed of absorption, which depends on several factors (e.g., the dose, route and place of administration), so the action profile of insulin is subject to considerable variation, both in different people and in the same person. On average, after subcutaneous administration, Rinsulin P begins to act in 30 minutes, with maximum effect developing between 1 and 3 hours, with a duration of action of 8 hours.

Pharmacokinetics

The completeness of absorption and onset of effect of insulin depends on the route of administration (subcutaneous, intramuscular, intravenous), site of administration (stomach, thigh, buttocks), dose (amount of injected insulin), the concentration of insulin in the drug, etc. Distributed irregularly in tissues; does not penetrate through placental barrier and into breast milk. It is broken down by insulinase mainly in liver and kidneys. The elimination half-life is several minutes. It is excreted by the kidneys (30-80%).

Indications

Composition

How to take, the dosage

Interaction

Special Instructions

During insulin therapy, continuous monitoring of blood glucose concentrations is necessary.

The causes of hypoglycemia in addition to insulin overdose may be: changing the drug, skipping meals, vomiting, diarrhea, increased physical activity, diseases that reduce the need for insulin (liver and kidney function disorders, adrenal gland, pituitary or thyroid hypofunction), change of injection site, and interaction with other medications.

Inadequate dosing or intermittent insulin administration, especially in patients with type 1 diabetes, can lead to hyperglycemia. Usually the first symptoms of hyperglycemia develop gradually over a few hours or days. They include the appearance of thirst, increased frequency of urination, nausea, vomiting, dizziness, red and dry skin, dry mouth, loss of appetite, and the smell of acetone in the exhaled air. If left untreated, hyperglycemia in type 1 diabetes can lead to life-threatening diabetic ketoacidosis.

The insulin dose should be adjusted for thyroid dysfunction, Addison’s disease, hypopituitarism, hepatic and renal dysfunction, and diabetes mellitus in individuals over 65 years of age.

The insulin dose may also need to be adjusted if the patient increases physical activity or changes their diet.

Concomitant illnesses, particularly infections and conditions with fever, increase the need for insulin.

The patient should be switched to a new type of insulin or to an insulin product from another manufacturer under the supervision of a physician.

Due to the potential for precipitation in some catheters, use of the product in insulin pumps is not recommended.

Impact on ability to drive and operate vehicles

In connection with the initial prescription of insulin, a change in its type, or in the presence of significant physical or mental stress, it is possible to impair the ability to drive vehicles or various moving mechanisms, as well as to engage in other potentially dangerous activities requiring increased attention and rapidity of reaction.

Contraindications

Side effects

Overdose

Pregnancy use